5243482026-04-012026-06-305243482026-04-012026-06-30in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares524348AARTIDRUGSNOTLISTEDINE767A01016AARTI DRUGS LIMITEDMain BoardEquity2026-04-012027-03-312026-07-312026-07-24INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2026-07-3114:30:002026-07-3117:20:00Not applicablefalsefalseThe disclosure for the defualt on Loans and Debt Securities is not applicable to the Company as there is no defualt.2026-04-012026-06-30AuditedStandalone6274500000200000062765000004345600000124500000-5766000002634000006950000015210000011986000005577100000699400000-2090000067850000016000000010000000170000000050850000000005085000000508500000912700000105.575.57005.575.571. The above results for the Quarter ended 30th June, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 31st July, 2026. <br /> <br /> 2. Exceptional item represents the write-off of Capital Work-in-Progress (CWIP) of Rs. 2.09 Cr. pertaining to the administrative building situated at E1, as an routine expansion plans. <br /> <br /> 3. Company has only one business segment i.e. pharmaceuticals. <br /> <br /> 4. Statutory Auditors have carried out audit of the above financials results for the quarter ended June 30, 2026 and have expressed unmodified audit opinion. <br /> <br /> 5. Figures for the previous Quarter have been regrouped or rearranged wherever necessary. <br /> <br /> 6. The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.co.in and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. <br /> <br /> <br /> For AARTI DRUGS LIMITED <br /> <br /> Sd/- <br /> Prakash M. Patil <br /> (Chairman, Managing Director & CEO) <br /> DIN :00005618 <br /> <br /> <br /> Place: Mumbai <br /> Date: 31st July, 2026 <br /> <br /> Other Expenses1198600000